In this context, considering a previously published fixed breast cancer gene panel that demands fewer sequencing resources46, and discarding TP53 and PIK3CA mutations already present in the panel, we found that all patients’ tumors exhibited somatic mutations suitable for tracking in their blood samples using the proposed methodology (Supplementary Fig. 10). This evidence concerns the gene TP53 and breast cancer.